Feature

AngioJet Rheolytic Thrombectomy During Rescue PCI for Failed Thrombolysis: A Single-Center Experience

Dimitri A. Sherev, MD, David M. Shavelle, MD, Murrad Abdelkarim, MD, Thomas Shook, MD, Guy S. Mayeda, MD, Steven Burstein, MD, Ray V. Matthews, MD
Dimitri A. Sherev, MD, David M. Shavelle, MD, Murrad Abdelkarim, MD, Thomas Shook, MD, Guy S. Mayeda, MD, Steven Burstein, MD, Ray V. Matthews, MD
Percutaneous coronary intervention (PCI) for acute myocardial infarction (MI) in the setting of angiographic thrombus is associated with an increased risk of reocclusion and recurrent infarction.1,2 Distal embolization of thrombus during PCI is thought to be a major contributor to impaired tissue level perfusion. Previous studies have shown the efficacy of AngioJet Rheolytic Thrombectomy (Possis Medical, Minneapolis, Minnesota) in reducing thrombus burden and improving coronary flow.3,4 However, no study to date has specifically evaluated the use of AngioJet Rheolytic Thrombectomy (RT) in patients undergoing rescue PCI for failed thrombolytics. Given the high thrombus burden in this setting, AngioJet RT would be expected to be particularly useful and associated with marked improvements in thrombus burden and coronary flow. The objectives of this study were to characterize the safety and efficacy and to perform a detailed angiographic analysis of AngioJet RT in patients undergoing rescue PCI for failed thrombolysis. Methods Study population. Two hundred and fourteen consecutive patients were transferred to Good Samaritan Hospital in Los Angeles, California from January 2000 through October 2004 to undergo rescue PCI for failed thrombolysis. The definition of failed thrombolysis was established on clinical grounds and made by the referring physician. All patients had ongoing chest pain, continued ST-segment elevation, hemodynamic instability or malignant ventricular arrhythmias and required transfer for emergent coronary angiography. All patients (n = 214) underwent emergent coronary angiography within 6 hours of arrival. Thirty-two patients (15%) underwent AngioJet RT because of intracoronary thrombus per physician discretion (RT group, n = 32). A group of 32 control patients were identified by matching patients based on infarct related artery (IRA) location and initial thrombolysis in MI (TIMI) flow grade (control group, n = 32). Interventional procedures and definitions. Cardiogenic shock was defined as systolic blood pressure
References
References 1. Ellis SG, Roubin GS, King SB, III, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372–379. 2. Singh M, Berger PB, Ting HH, et al. Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). Am J Cardiol 2001;88:1091–1096. 3. Silva JA, Ramee SR, Cohen DJ, et al. Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: Experience with the AngioJet catheter. Am Heart J 2001;141:353–359. 4. Kuntz RE, Baim DS, Cohen DJ, et al. A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). Am J Cardiol 2002;89:326–330. 5. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673–682. 6. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142–154. 7. Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy. Circulation 2001;103:2550–2554. 8. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93:879–888. 9. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486–502. 10. Topaz O. On the hostile massive thrombus and the means to eradicate it. Catheter Cardiovasc Interv 2005;65:280–281. 11. Lim MJ, Reis L, Ziaee A, Kern MJ. Use of a new thrombus extraction catheter (the Pronto) in the treatment of acute myocardial infarction. J Interv Cardiol 2005;18:189–192. 12. Lefevre T, Garcia E, Reimers B, et al. X-sizer for thrombectomy in acute myocardial infarction improves ST-segment resolution: Results of the X-sizer in AMI for negligible embolization and optimal ST resolution (X AMINE ST) trial. J Am Coll Cardiol 2005;46:246–252. 13. Silva JA, Ramee SR, Cohen DJ, et al. Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: Experience with the AngioJet catheter. Am Heart J 2001;141:353–359. 14. Nakagawa Y, Matsuo S, Yokoi H, et al. Stenting after thrombectomy with the AngioJet catheter for acute myocardial infarction. Cathet Cardiovasc Diagn 1998;43:327–330. 15. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. “Rescue” utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997;30:1729–1734. 16. Petronio AS, De CM, Rossini R, et al. Role of platelet glycoprotein IIb/IIIa inhibitors in rescue percutaneous coronary interventions. Ital Heart J 2004;5:114–119. 17. Jong P, Cohen EA, Batchelor W, et al. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. Am Heart J 2001;141:218–225. 18. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202–1209. 19. Feld H, Lichstein E, Schachter J, Shani J. Early and late angiographic findings of the “no-reflow” phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992;123:782–784. 20. Romano M, Buffoli F, Lettieri C, et al. No reflow in patients undergoing primary angioplasty for acute myocardial infarction at high risk: Incidence and predictive factors. Minerva Cardioangiol 2005;53:7–14. 21. Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: The Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004;44:287–296. 22. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005;353:2758–2768.